Literature DB >> 9165696

Management of refractory and complicated reflux esophagitis.

B I Hirschowitz1.   

Abstract

Simple intermittent heartburn with minor or no esophagitis can be treated with simple measures including lifestyle changes and antacids as needed, or H2 receptor antagonists (H2RA), and has a good outcome. Problematic reflux includes resistance to therapy, stricture, Barrett's esophagus and aspiration. Severe reflux esophagitis, often resistant to H2RA therapy, requires more potent treatment with potent acid suppression using proton pump inhibitors, often indefinitely. When complicated by stricture, dilatations with potent acid suppression are needed. Barrett's esophagus is subject to esophagitis, which is no more difficult to treat than other cases of esophagitis. Reflux in Barrett's esophagus should be treated on its own merits without regard to the presence of Barrett's epithelium. Dysplasia leading to adenocarcinoma is a different problem, apparently not influenced by reduced exposure to acid. Indications for antireflux surgery are quite limited and should be carefully analyzed as a cost/risk/benefit problem.

Entities:  

Mesh:

Year:  1996        PMID: 9165696      PMCID: PMC2589006     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  62 in total

1.  Surgery for reflux disease: reflections of a gastroenterologist.

Authors:  J E Richter
Journal:  N Engl J Med       Date:  1992-03-19       Impact factor: 91.245

Review 2.  Pill-induced esophageal strictures: clinical features and risk factors for development.

Authors:  G S McCord; R E Clouse
Journal:  Am J Med       Date:  1990-05       Impact factor: 4.965

Review 3.  Reflux stricture of the oesophagus.

Authors:  A Watson
Journal:  Br J Surg       Date:  1987-06       Impact factor: 6.939

Review 4.  Rationale and efficacy of conservative therapy for gastroesophageal reflux disease.

Authors:  L I Kitchin; D O Castell
Journal:  Arch Intern Med       Date:  1991-03

5.  Effect of cigarette smoking on gastroesophageal reflux measured by 24-h ambulatory esophageal pH monitoring.

Authors:  S C Kadakia; J W Kikendall; C Maydonovitch; L F Johnson
Journal:  Am J Gastroenterol       Date:  1995-10       Impact factor: 10.864

6.  Self-Directed Treatment of Intermittent Heartburn: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Evaluation of Antacid and Low Doses of an H(2)-Receptor Antagonist (Famotidine).

Authors:  Thomas J. Simon; Roger G. Berlin; Andrea H. Gardner; Laura A. Stauffer; A. Lawrence Gould; Albert J. Getson
Journal:  Am J Ther       Date:  1995-05       Impact factor: 2.688

7.  Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma.

Authors:  D A Katzka; J C Reynolds; S H Saul; A Plotkin; C A Lang; A Ouyang; S Jimenez; S Cohen
Journal:  Am J Med       Date:  1987-01       Impact factor: 4.965

Review 8.  Controlled clinical trials of omeprazole in the long-term management of reflux disease.

Authors:  D J Hetzel
Journal:  Digestion       Date:  1992       Impact factor: 3.216

9.  Esophageal function in patients with reflux-induced strictures and its relevance to surgical treatment.

Authors:  G Zaninotto; T R DeMeester; C G Bremner; T C Smyrk; S C Cheng
Journal:  Ann Thorac Surg       Date:  1989-03       Impact factor: 4.330

10.  Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis.

Authors:  R D Marks; J E Richter; J Rizzo; R E Koehler; J G Spenney; T P Mills; G Champion
Journal:  Gastroenterology       Date:  1994-04       Impact factor: 22.682

View more
  1 in total

1.  Gastroesophageal reflux disease: clinical features.

Authors:  Michael Pettit
Journal:  Pharm World Sci       Date:  2005-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.